Oral vitamin C supplementation in patients with clonal cytopenia of undetermined significance or lower-risk myeloid malignancies: Results from EVITA, a phase 2 randomized, placebo-controlled trial.

In 30 seconds

The EVITA trial, a phase 2 randomized controlled trial, evaluated oral vitamin C supplementation in 109 adults with clonal cytopenia of undetermined significance or lower-risk myeloid malignancies. While the primary endpoint of median clonal growth rate showed no significant difference between groups, exploratory analyses indicated a significantly longer overall survival with vitamin C (hazard ratio, 0.35; p = .0025).

Key findings

• No significant difference in median clonal growth rate between vitamin C and placebo groups (p = .70).
• Fewer serious adverse events in the vitamin C group (33%) compared to placebo (57%).
• Overall survival was significantly longer with vitamin C (hazard ratio, 0.35; p = .0025).

Why it matters

The study suggests that oral vitamin C may be a safe intervention with potential benefits in overall survival for patients with early-stage myeloid malignancies, highlighting the need for further research in this area.